Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Ault

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|June 5, 2009
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialNubia Muñoz, Ricardo Manalastas, Punee Pitisuttithum, et al.
Vaccine|August 3, 2013
Research on vaccines during pregnancy: protocol design and assessment of safetyFlor M Munoz, Jeanne S Sheffield, Richard H Beigi, et al.
Vaccines|July 8, 2020
Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 ExposureLilin Lai, Kevin Ault, Nadine Rouphael, et al.
Vaccine|July 11, 2022
Multi-tiered intervention to increase maternal immunization coverage: A randomized, controlled trialSaad B Omer, Sean T O'Leary, Robert A Bednarczyk, et al.
Vaccine|December 1, 2019
Chorioamnionitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety dataAlisa Kachikis, Linda O Eckert, Christie Walker, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|June 5, 2009
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialNubia Muñoz, Ricardo Manalastas, Punee Pitisuttithum, et al.
Vaccine|August 3, 2013
Research on vaccines during pregnancy: protocol design and assessment of safetyFlor M Munoz, Jeanne S Sheffield, Richard H Beigi, et al.
Vaccines|July 8, 2020
Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 ExposureLilin Lai, Kevin Ault, Nadine Rouphael, et al.
Vaccine|July 11, 2022
Multi-tiered intervention to increase maternal immunization coverage: A randomized, controlled trialSaad B Omer, Sean T O'Leary, Robert A Bednarczyk, et al.
Vaccine|December 1, 2019
Chorioamnionitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety dataAlisa Kachikis, Linda O Eckert, Christie Walker, et al.
Pageof 5